Literature DB >> 35285721

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.

William E Rosa1, Zachary Sager2, Megan Miller3, Ilan Bernstein4, Alden Doerner Rinaldi5, Katie Addicott6, Michael Ljuslin2,7, Chris Adrian8, Anthony L Back9, Jamie Beachy10, Anthony P Bossis11,12, William S Breitbart1, Mary P Cosimano13, Stacy M Fischer14, Jeffrey Guss11,15, Emma Knighton16, Janis Phelps17, Brian D Richards13,18, William A Richards13,18, James A Tulsky2, Monnica T Williams19, Yvan Beaussant2.   

Abstract

Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within the palliative care (PC) field, one-time PAT dosing may lead to sustained reductions in anxiety, depression, and demoralization-symptoms that diminish the quality of life in both seriously ill patients and those at end of life. Despite a well-noted psychedelic renaissance in scholarship and a renewed public interest in the utilization of these medicines, serious illness-specific content to guide PAT applications in hospice and PC clinical settings has been limited. This article offers 10 evidence-informed tips for PC clinicians synthesized through consultation with interdisciplinary and international leading experts in the field with aims to: (1) familiarize PC clinicians and teams with PAT; (2) identify the unique challenges pertaining to this intervention given the current legalities and logistical barriers; (3) discuss therapeutic competencies and considerations for current and future PAT use in PC; and (4) highlight critical approaches to optimize the safety and potential benefits of PAT among patients with serious illness and their caregivers.

Entities:  

Keywords:  LSD; MDMA; anxiety treatment; demoralization; depression; palliative care; psilocybin; psychedelic-assisted therapy; psychedelics; serious illness

Mesh:

Substances:

Year:  2022        PMID: 35285721      PMCID: PMC9467634          DOI: 10.1089/jpm.2022.0036

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  51 in total

Review 1.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.

Authors:  Franz X Vollenweider; Michael Kometer
Journal:  Nat Rev Neurosci       Date:  2010-08-18       Impact factor: 34.870

2.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

3.  Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.

Authors:  Avinash Hosanagar; Joseph Cusimano; Rajiv Radhakrishnan
Journal:  J Clin Psychiatry       Date:  2021-02-23       Impact factor: 4.384

4.  Psychedelic medicine: safety and ethical concerns.

Authors:  Brian T Anderson; Alicia L Danforth; Charles S Grob
Journal:  Lancet Psychiatry       Date:  2020-10       Impact factor: 27.083

5.  Neuroticism is associated with challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  Pers Individ Dif       Date:  2017-06-07

Review 6.  MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis.

Authors:  Kimberly W Smith; Dakota J Sicignano; Adrian V Hernandez; C Michael White
Journal:  J Clin Pharmacol       Date:  2021-11-28       Impact factor: 3.126

Review 7.  Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.

Authors:  Stephen Ross
Journal:  Int Rev Psychiatry       Date:  2018-08-13

8.  Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives.

Authors:  Yvan Beaussant; Justin Sanders; Zachary Sager; James A Tulsky; Ilana M Braun; Craig D Blinderman; Anthony P Bossis; Ira Byock
Journal:  J Palliat Med       Date:  2020-04-01       Impact factor: 2.947

9.  Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.

Authors:  Stephen Ross; Gabrielle Agin-Liebes; Sharon Lo; Richard J Zeifman; Leila Ghazal; Julia Benville; Silvia Franco Corso; Christian Bjerre Real; Jeffrey Guss; Anthony Bossis; Sarah E Mennenga
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-18

10.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.